242 related articles for article (PubMed ID: 33274245)
1. Systemic Inflammation Response Index Predicts Survival Outcomes in Glioblastoma Multiforme Patients Treated with Standard Stupp Protocol.
Topkan E; Kucuk A; Ozdemir Y; Mertsoylu H; Besen AA; Sezen D; Bolukbasi Y; Pehlivan B; Selek U
J Immunol Res; 2020; 2020():8628540. PubMed ID: 33274245
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide.
Topkan E; Besen AA; Ozdemir Y; Kucuk A; Mertsoylu H; Pehlivan B; Selek U
Mediators Inflamm; 2020; 2020():4392189. PubMed ID: 32565725
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide.
Topkan E; Kucuk A; Selek U
J Immunol Res; 2022; 2022():1346094. PubMed ID: 36479136
[TBL] [Abstract][Full Text] [Related]
4. Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy.
Topkan E; Mertsoylu H; Kucuk A; Besen AA; Sezer A; Sezen D; Bolukbasi Y; Selek U; Pehlivan B
Gastroenterol Res Pract; 2020; 2020():5701949. PubMed ID: 32802045
[TBL] [Abstract][Full Text] [Related]
5. In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator.
Chen L; Chen Y; Zhang L; Xue Y; Zhang S; Li X; Song H
Pathol Oncol Res; 2021; 27():1609811. PubMed ID: 34712105
[No Abstract] [Full Text] [Related]
6. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy.
Kucuk A; Ozkan EE; Eskici Oztep S; Mertsoylu H; Pehlivan B; Selek U; Topkan E
J Oncol; 2020; 2020():8832145. PubMed ID: 33381177
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy.
Brenner A; Friger M; Geffen DB; Kaisman-Elbaz T; Lavrenkov K
Oncology; 2019; 97(5):255-263. PubMed ID: 31288238
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of the preoperative inflammatory index on the survival of glioblastoma patients.
Shi X; Li H; Xu Y; Nyalali AMK; Li F
Neurol Sci; 2022 Sep; 43(9):5523-5531. PubMed ID: 35606674
[TBL] [Abstract][Full Text] [Related]
10. The Prognostic Significance of Novel Pancreas Cancer Prognostic Index in Unresectable Locally Advanced Pancreas Cancers Treated with Definitive Concurrent Chemoradiotherapy.
Topkan E; Selek U; Pehlivan B; Kucuk A; Haksoyler V; Kilic Durankus N; Sezen D; Bolukbasi Y
J Inflamm Res; 2021; 14():4433-4444. PubMed ID: 34511977
[TBL] [Abstract][Full Text] [Related]
11. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
12. Combining the systemic inflammation response index and prognostic nutritional index to predict the prognosis of locally advanced elderly esophageal squamous cell carcinoma patients undergoing definitive radiotherapy.
Yan K; Wei W; Shen W; Du X; Zhu S; Zhao H; Wang X; Yang J; Zhang X; Deng W
J Gastrointest Oncol; 2022 Feb; 13(1):13-25. PubMed ID: 35284132
[TBL] [Abstract][Full Text] [Related]
13. Guideline conformity to the Stupp regimen in patients with newly diagnosed glioblastoma multiforme in China.
Wang Y; Zhang J; Li W; Jiang T; Qi S; Chen Z; Kang J; Huo L; Wang Y; Zhuge Q; Gao G; Wu Y; Feng H; Zhao G; Yang X; Zhao H; Wang Y; Yang H; Kang D; Su J; Li L; Jiang C; Li G; Qiu Y; Wang W; Wang H; Xu Z; Zhang L; Wang R
Future Oncol; 2021 Nov; 17(33):4571-4582. PubMed ID: 34519220
[TBL] [Abstract][Full Text] [Related]
14. Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis.
Topkan E; Selek U; Kucuk A; Haksoyler V; Ozdemir Y; Sezen D; Mertsoylu H; Besen AA; Bolukbasi Y; Ozyilkan O; Pehlivan B
J Oncol; 2021; 2021():6688138. PubMed ID: 33552158
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
[TBL] [Abstract][Full Text] [Related]
16. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
17. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
18. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer.
Pacheco-Barcia V; Mondéjar Solís R; France T; Asselah J; Donnay O; Zogopoulos G; Bouganim N; Guo K; Rogado J; Martin E; Alcindor T; Colomer R
Pancreatology; 2020 Mar; 20(2):254-264. PubMed ID: 31866391
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment systemic inflammation response index (SIRI) is an independent predictor of survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy: a two-center retrospective study.
Hu M; Xu Q; Yang S; Han S; Zhu Y; Lin Q; Sun X; Liu H; Xu Y
Ann Transl Med; 2020 Oct; 8(20):1310. PubMed ID: 33209890
[TBL] [Abstract][Full Text] [Related]
20. Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival.
Huang B; Yu Z; Liang R
BMC Neurol; 2021 Nov; 21(1):424. PubMed ID: 34724914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
